奈非那韦耐药性突变对具有B型和C型蛋白酶的1型人类免疫缺陷病毒体外表型、适应性和复制能力的影响。
Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases.
作者信息
Gonzalez Luis M F, Brindeiro Rodrigo M, Aguiar Renato S, Pereira Helena S, Abreu Celina M, Soares Marcelo A, Tanuri Amilcar
机构信息
Laboratório de Virologia Molecular, Departamento de Genética, Universidade Federal do Rio de Janeiro, CCS, Bloco A, Cidade Universitária, Ilha do Fundão, 21944-970 Rio de Janeiro, RJ, Brazil.
出版信息
Antimicrob Agents Chemother. 2004 Sep;48(9):3552-5. doi: 10.1128/AAC.48.9.3552-3555.2004.
Abstract
Human immunodeficiency virus type 1 subtype B and C proteases were manipulated to contain 90M, 88D, or 89L, and their in vitro biological properties were studied. We showed that D30N has significantly more impact in subtype C than in subtype B counterparts, accounting for the reported low prevalence of this mutation in patients failing nelfinavir-based regimens.
摘要
对1型人类免疫缺陷病毒B亚型和C亚型蛋白酶进行改造，使其含有90M、88D或89L，并研究了它们的体外生物学特性。我们发现，D30N对C亚型的影响比对B亚型对应物的影响要大得多，这解释了在基于奈非那韦的治疗方案失败的患者中该突变报告的低发生率。
相似文献
1
Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases.奈非那韦耐药性突变对具有B型和C型蛋白酶的1型人类免疫缺陷病毒体外表型、适应性和复制能力的影响。
Antimicrob Agents Chemother. 2004 Sep;48(9):3552-5. doi: 10.1128/AAC.48.9.3552-3555.2004.
2
Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.在对奈非那韦产生耐药性的过程中，1型人类免疫缺陷病毒C亚型不会优先选择D30N突变。
Antimicrob Agents Chemother. 2004 Jun;48(6):2159-65. doi: 10.1128/AAC.48.6.2159-2165.2004.
3
Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.1型人类免疫缺陷病毒C亚型对博茨瓦纳接受含奈非那韦方案治疗失败患者耐药性突变的影响。
Antimicrob Agents Chemother. 2006 Jun;50(6):2210-3. doi: 10.1128/AAC.01447-05.
4
Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.通过分子动力学模拟理解 HIV-1 蛋白酶奈非那韦耐药突变 D30N 在亚型 B 和 C 中的作用。
J Mol Graph Model. 2010 Sep;29(2):137-47. doi: 10.1016/j.jmgm.2010.05.007. Epub 2010 Jun 11.
5
Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.在基于奈非那韦和洛匹那韦/利托那韦的治疗出现病毒学失败后，HIV-1蛋白酶中的突变模式及相关氨基酸替换
J Med Virol. 2007 Nov;79(11):1617-28. doi: 10.1002/jmv.20986.
6
Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.在使用奈非那韦治疗失败的HIV-1感染患者中，蛋白酶抑制剂耐药突变的多样模式。
J Med Virol. 2005 Aug;76(4):447-51. doi: 10.1002/jmv.20381.
7
Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.HIV-1蛋白酶突变A71V/T和T74S对G亚型分离株中M89I/V介导的蛋白酶抑制剂耐药性的影响
J Antimicrob Chemother. 2008 Jun;61(6):1201-4. doi: 10.1093/jac/dkn099. Epub 2008 Mar 20.
8
Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly.携带蛋白酶N88S突变的1型人类免疫缺陷病毒的奈非那韦耐药、安普那韦超敏菌株具有降低的感染性、复制能力和适应性，并异常加工Gag多蛋白前体。
J Virol. 2002 Sep;76(17):8659-66. doi: 10.1128/jvi.76.17.8659-8666.2002.
9
HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G.HIV-1 蛋白酶突变 82M 导致 G 亚型对蛋白酶抑制剂的表型耐药。
J Antimicrob Chemother. 2012 May;67(5):1075-9. doi: 10.1093/jac/dks010. Epub 2012 Feb 13.
10
Parameters driving the selection of nelfinavir-resistant human immunodeficiency virus type 1 variants.驱动对奈非那韦耐药的1型人类免疫缺陷病毒变体选择的参数。
J Virol. 2003 Sep;77(18):10172-5. doi: 10.1128/jvi.77.18.10172-10175.2003.
引用本文的文献
1
Consensus Sequences for and Introduced into HIV-1 Clade B Laboratory Strains Differentially Influence the Impact of Point Mutations Associated with Immune Escape and with Drug Resistance on Viral Replicative Capacity.引入HIV-1 B亚型实验室毒株的[具体内容]和[具体内容]的共有序列对与免疫逃逸及耐药相关的点突变对病毒复制能力的影响产生不同作用。
Viruses. 2025 Jun 12;17(6):842. doi: 10.3390/v17060842.
2
2022 update of the drug resistance mutations in HIV-1.2022 年 HIV-1 耐药突变更新。
Top Antivir Med. 2022 Oct;30(4):559-574.
3
New antiretroviral inhibitors and HIV-1 drug resistance: more focus on 90% HIV-1 isolates?新型抗逆转录病毒抑制剂与 HIV-1 耐药性：更多关注 90% 的 HIV-1 分离株？
FEMS Microbiol Rev. 2023 Jan 16;47(1). doi: 10.1093/femsre/fuac040.
4
2019 update of the drug resistance mutations in HIV-1.2019年人类免疫缺陷病毒1型耐药性突变的更新情况。
Top Antivir Med. 2019 Sep;27(3):111-121.
5
Characterization of the Drug Resistance Profiles of Patients Infected with CRF07_BC Using Phenotypic Assay and Ultra-Deep Pyrosequencing.使用表型分析和超深度焦磷酸测序对感染CRF07_BC的患者的耐药谱进行表征。
PLoS One. 2017 Jan 20;12(1):e0170420. doi: 10.1371/journal.pone.0170420. eCollection 2017.
6
More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1.在HIV-1耐药性的演变过程中，更有效的药物会导致更强烈的选择性清除。
Elife. 2016 Feb 15;5:e10670. doi: 10.7554/eLife.10670.
7
Pulsed EPR characterization of HIV-1 protease conformational sampling and inhibitor-induced population shifts.HIV-1蛋白酶构象采样及抑制剂诱导的种群转移的脉冲电子顺磁共振表征
Phys Chem Chem Phys. 2016 Feb 17;18(8):5819-31. doi: 10.1039/c5cp04556h.
8
The impact of wild-type reversion on transmitted resistance surveillance.野生型回复对传播耐药性监测的影响。
Antivir Ther. 2014;19(7):719-22. doi: 10.3851/IMP2746. Epub 2014 Feb 17.
9
HIV-1 Genetic Variability and Clinical Implications.HIV-1基因变异性及其临床意义。
ISRN Microbiol. 2013 Jun 17;2013:481314. doi: 10.1155/2013/481314. Print 2013.
10
The Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs.人类免疫缺陷病毒（HIV）基因多态性和亚型差异对抗逆转录病毒药物耐药性发生的影响
Mol Biol Int. 2012;2012:256982. doi: 10.1155/2012/256982. Epub 2012 Jun 26.
本文引用的文献
1
Parameters driving the selection of nelfinavir-resistant human immunodeficiency virus type 1 variants.驱动对奈非那韦耐药的1型人类免疫缺陷病毒变体选择的参数。
J Virol. 2003 Sep;77(18):10172-5. doi: 10.1128/jvi.77.18.10172-10175.2003.
2
In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir.1型人类免疫缺陷病毒C亚型蛋白酶对洛匹那韦的体外超敏感性
Antimicrob Agents Chemother. 2003 Sep;47(9):2817-22. doi: 10.1128/AAC.47.9.2817-2822.2003.
3
Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection.与CRF01_AE（E亚型）感染中抗逆转录病毒药物治疗失败相关的点突变模式与B亚型感染不同。
J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):336-42. doi: 10.1097/00126334-200307010-00007.
4
Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments.1型人类免疫缺陷病毒蛋白酶在不同蛋白酶抑制剂治疗后的突变模式及结构关联
J Virol. 2003 Apr;77(8):4836-47. doi: 10.1128/jvi.77.8.4836-4847.2003.
5
Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pretreated patients.初治和经治患者中人类免疫缺陷病毒p7-p1-p6 gag基因的变化
J Clin Microbiol. 2003 Mar;41(3):1245-7. doi: 10.1128/JCM.41.3.1245-1247.2003.
6
Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.从抗逆转录病毒治疗失败患者中分离出的HIV毒株的复制能力、生物学表型及耐药性
J Med Virol. 2003 Jan;69(1):1-6. doi: 10.1002/jmv.10269.
7
Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons.在一类来自未接受过治疗人群的野生型HIV-1中，齐多夫定耐药性的选择能力增强。
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13907-12. doi: 10.1073/pnas.241300698. Epub 2001 Nov 6.
8
Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein.由1型人类免疫缺陷病毒p6蛋白介导的对核苷类似物逆转录酶抑制剂的耐药性
J Virol. 2001 Oct;75(20):9644-53. doi: 10.1128/JVI.75.20.9644-9653.2001.
9
Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom.来自英国接受治疗和未接受治疗患者的1型人类免疫缺陷病毒C亚型蛋白酶基因中的耐药相关突变。
J Clin Microbiol. 2001 Jul;39(7):2652-4. doi: 10.1128/JCM.39.7.2652-2654.2001.
10
Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.与茚地那韦、利托那韦和/或沙奎那韦选择的蛋白酶抑制剂交叉耐药相关的1型人类免疫缺陷病毒蛋白酶切割位点突变。
J Virol. 2001 Jan;75(2):589-94. doi: 10.1128/JVI.75.2.589-594.2001.
Zotero 插件